 |
|
|
|
|
|
|
|
 |
Results for 'Developing Markets for Pharmaceuticals, 2006-2011' |
|
|
| Title |
 |
Publication Date |
|
Price |
|
Relevance |
 |
|
|
|
|
Latin American Developing Markets for Pharmaceuticals, 2006-2011
|
November 2006 |
£1999 |
100 % |
Central and Eastern European (CEE) Developing Markets for Pharmaceuticals, 2006-2011
|
November 2006 |
£1999 |
32.2 % |
World Asthma and COPD Treatment Market, 2006-2011, The
A Changing Market with Increasing Potential
|
September 2006 |
£1499 |
26.25 % |
Achieving success in the Developing Asian Pharmaceutical Sector 2007-2011
|
November 2006 |
£1999 |
25.55 % |
Auxilium Pharmaceuticals Inc - SWOT Analysis
|
November 2007 |
£63 |
25 % |
New Anticoagulant Therapies
A Market Briefing
|
October 2004 |
£600 |
23.5 % |
Millennium Pharmaceuticals Inc
Premium Company Profile
|
December 2007 |
£265 |
23.5 % |
Transdermal Drug Delivery
Technologies, Markets, and Companies
|
September 2008 |
£1675 |
22.5 % |
Lev Pharmaceuticals Inc
Premium Company Profile
|
April 2008 |
£265 |
21.5 % |
Somaxon Pharmaceuticals Inc
Premium Company Profile
|
March 2008 |
£265 |
21.5 % |
Emerging Generic Drug Companies Worldwide 2007
|
February 2007 |
£595 |
20.5 % |
Regeneron Pharmaceuticals Inc
Premium Company Profile
|
December 2007 |
£265 |
20 % |
Molecular Diagnostics
Technologies, Markets and Companies
|
September 2008 |
£3020 |
19.5 % |
Anti Addiction Therapies, 2006-2011- The Pharmaceutical Industry's Next Viagra?
|
October 2006 |
£1499 |
19.5 % |
QLT Inc: Premium Company Profile
Premium Company Profile
|
January 2008 |
£265 |
19.5 % |
Indian Pharmaceutical Market, 2006-2011
|
June 2006 |
£1499 |
18.55 % |
Optimer Pharmaceuticals Inc: Premium Company Profile
|
February 2008 |
£265 |
18.5 % |
Insulin Delivery Systems Market Analysis (2007-2010)
|
May 2007 |
£940 |
18.2 % |
Pharmaceutical Markets in Brazil, Russia, India and China (Bric Nations)
|
July 2008 |
£1185 |
17.85 % |
Market Development in Anti-virals:What is Next?
What is Next?
|
August 2004 |
£415 |
17.5 % |
Optimer Pharmaceuticals Inc
Premium Company Profile
|
April 2008 |
£265 |
17.5 % |
A Guide to Biosimilars, Biogenerics and Follow-on Biologics
|
January 2007 |
£1095 |
17.15 % |
Tanabe Prospects to 2010
Pipeline, Products,Performance,Potential
|
September 2007 |
£595 |
17 % |
Companion Animal Health Products: New edition
|
January 2006 |
£795 |
16.5 % |
World Market for Addiction Disorders 2005-2012, The
New Horizons in High-Profile Dependency Markets
|
December 2005 |
£1100 |
16.5 % |
Vaccines
|
March 2008 |
£600 |
16.45 % |
New Drug Futures: Cancer Chapter
|
May 2006 |
£695 |
16.1 % |
World Market for Sexual Disorders, 2005-2012, The
Traversing New Frontiers in Sexual Chemistry
|
January 2006 |
£1900 |
16 % |
Pipeline Insight: Upper GI Disorders - Generics will limit pipeline profit
|
July 2007 |
£6000 |
16 % |
C-MAP Canadian Drug Benefit Plans Reference Guide 2006 Edition
|
January 2006 |
£2195 |
15.5 % |
Global Image Dermatology Drug Market, 2005-2012, The
High-Growth Opportunities in Aesthetic Medicine
|
November 2005 |
£1900 |
15.5 % |
World Generics Market 2006-2011; The
|
May 2006 |
£1499 |
15.4 % |
Drug Delivery Technology: Developing a New Generation of Vaccines
|
November 2007 |
£945 |
15.4 % |
New Drug Futures: Alimentary/Metabolic Chapter
|
May 2006 |
£695 |
15.05 % |
Global Market for Antimicrobials and Antifungals; The
Challenging Resistance to 2016
|
December 2006 |
£1600 |
14.7 % |
Generic Series: An Introduction to the Canadian Generics Market
Key trends and leading companies shaping the market
|
June 2007 |
£2000 |
14.7 % |
New Drug Futures: Cardiovascular Chapter
|
May 2006 |
£695 |
14.7 % |
The Indian Pharmaceutical Market Analysis and Forecasts 2008-2023
|
May 2008 |
£1499 |
14.5 % |
Cancer Drug Discoveries: Prostate Cancer
|
August 2005 |
£795 |
14.5 % |
Panacos Pharmaceuticals Inc
Premium Company Profile
|
April 2008 |
£265 |
14.5 % |
Asia Generic Pharmaceuticals Forecast Report; The
|
July 2006 |
£510 |
14.35 % |
Rimonabant: The first of the Cannabinoid blockbusters
|
June 2007 |
£1499 |
14.35 % |
Switzerland Pharmaceuticals & Healthcare
|
September 2006 |
£395 |
14 % |
New Drug Futures: Anti-Infective Chapter
|
May 2006 |
£695 |
14 % |
Urinary Tract Agents Report 2005
|
April 2005 |
£1499 |
14 % |
Global Antivirals Market Analysis & Forecasts 2008-2023
|
September 2008 |
£1499 |
14 % |
Opportunities in Drug Delivery
Identifying hot technologies, companies and markets
|
September 2003 |
£400 |
13.65 % |
Enzyme Inhibitors with Broad Therapeutic Applications
|
June 2006 |
£3255 |
13.65 % |
Novacea Inc
Premium Company Profile
|
April 2008 |
£265 |
13.5 % |
New Drug Futures: Musculoskeletal Chapter
|
May 2006 |
£695 |
13.3 % |
Brazil Pharmaceuticals & Healthcare Report Q3 2006
|
July 2006 |
£395 |
13 % |
Biomarkers: A Market Briefing
A Market Briefing
|
January 2007 |
£1340 |
13 % |
Drug Delivery Systems
US Market Outlook, Advances for Pharma, Biotech & Medical Devices
|
September 2006 |
£1540 |
12.95 % |
Angiogenesis Modulators
|
January 2008 |
£1880 |
12.95 % |
Global Markets for Antifungal Agents
|
March 2007 |
£3255 |
12.95 % |
Next-Generation Nutraceuticals
Food and pharma convergence in disease prevention and personalized nutrition
|
December 2006 |
£1495 |
12.95 % |
Nanomedicine 2006-2011
|
June 2006 |
£1499 |
12.6 % |
Who's Developing What in New Cancer Drugs 2006?
|
November 2007 |
£495 |
12.5 % |
Pakistan Pharmaceuticals and Healthcare Report Q3 2008
|
September 2008 |
£425 |
12.5 % |
Drug Delivery Technology: Revolutionizing Diabetes Treatment
|
September 2007 |
£945 |
12.5 % |
Drug Delivery Technology
Revolutionizing Diabetes Treatment
|
September 2007 |
£945 |
12.5 % |
Dr. Reddy's Market Outlook, Forecasts and Analysis to 2012
|
April 2007 |
£1499 |
12.25 % |
Top Companies and Products in the RNA/DNA Therapy Products Market Forecasts:
The Challenge Of Turning Technology Into Therapy
|
July 2007 |
£1999 |
12.25 % |
Dr. Reddy's Market Outlook, Forecasts and Analysis to 2012
|
April 2007 |
£1499 |
12.25 % |
Dr. Reddy's Market Outlook, Forecasts and Analysis to 2012
|
April 2007 |
£1499 |
12.25 % |
GSK's Cervarix
A Future Blockbuster of 2007
|
March 2007 |
£1999 |
12.25 % |
Dr. Reddy's Market Outlook, Forecasts and Analysis to 2012
|
April 2007 |
£1499 |
12.25 % |
Brazil Pharmaceuticals and Healthcare Report Q3 2008
|
September 2008 |
£425 |
12 % |
Global Clinical Trial Business Report & Analysis 2008-2018
|
July 2008 |
£2999 |
12 % |
Pharmaceutical Sales Management
Establishing Fair-Market Value Procedures
|
December 2007 |
£4690 |
12 % |
Defending Brand Revenue
Pharmaceutical Lifecycle Management Planning
|
July 2005 |
£2605 |
12 % |
The Outlook for Pharmaceuticals in Western Europe
|
March 2007 |
£1995 |
12 % |
Asia Pacific Biotechnology Market
2007-2010
|
June 2007 |
£1075 |
11.9 % |
Stem Cell Research
|
January 2008 |
£2850 |
11.9 % |
Asia Pacific Biotechnology Market
2007-2010
|
June 2007 |
£535 |
11.9 % |
Asia Pacific Biotechnology Market
2007-2010
|
June 2007 |
£535 |
11.9 % |
Pharmaceutical Distribution in Europe
The Emergence of Direct-to-Pharmacy Supply
|
February 2008 |
£995 |
11.9 % |
Anti-Obesity Treatments 2007-2012 - A blockbuster target market
|
July 2007 |
£1799 |
11.2 % |
Biomarkers & Related Tests for Molecular Diagnostics & Pharma/ Biotech R&D
Companies, Products & Worldwide Market, 2004-2009
|
July 2005 |
£1270 |
11.2 % |
Pharmaceutical Pricing, Reimbursement and Parallel Trade 2006
|
March 2006 |
£1340 |
11.2 % |
How Drugs Are Developed
3rd Edition
|
January 2007 |
£1095 |
11 % |
The OTC Animal Health Global Market Opportunity
|
January 2007 |
£895 |
11 % |
New Directions in Monoclonal Antibodies
Technologies, Markets, Competition
|
October 2004 |
£1950 |
10.85 % |
Scrip Yearbook 2007
23rd Edition (2 Volumes)
|
January 2006 |
£895 |
10.5 % |
Parallel Trade
US Lawmakers Allow Imported Prescriptions Drugs
|
June 2007 |
£1499 |
10.5 % |
World Pharmaceutical Wholesale and Distribution Industry, The
2005
|
January 2005 |
£1499 |
10.5 % |
Early Stage and Discovery Deals
Strategy, Structure and Payment Terms 2nd Edition
|
January 2007 |
£1350 |
10.5 % |
Pharmaceutical Wholesale and Distribution Industry Outlook & Analysis 2008, The
|
June 2008 |
£1499 |
10.5 % |
Outlook for RNAi, 2007
siRNA and miRNA in biology, diagnostics and therapeutics
|
June 2007 |
£1495 |
10.5 % |
Emerging Markets Series: The Pharmaceutical Market of South Korea
|
October 2008 |
£4000 |
10.15 % |
Medical Nanotechnology Markets
|
September 2008 |
£2280 |
10.15 % |
Generics Threats and Opportunities
Mounting an Effective Defense Strategy
|
June 2008 |
£497 |
10 % |
Intellectual property strategies for pharmaceutical development
|
May 2004 |
£600 |
10 % |
Drug Delivery Technology: Revolutionizing Cardiovascular Therapies
|
July 2007 |
£945 |
10 % |
Late Stage Deals
Strategy, Structure and Payment Terms
|
August 2004 |
£950 |
10 % |
Analyzing the Generic Drugs Sector of the US Pharmaceutical Industry
|
January 2008 |
£650 |
9.8 % |
Healthcare and Pharmaceuticals in Latin America
A guide to the markets and regulations
|
May 2005 |
£525 |
9.8 % |
High Throughput Screening
|
January 2008 |
£2060 |
9.8 % |
Biosimilars: a viable market?
|
September 2008 |
£1295 |
9.8 % |
A Healthy Business
A guide to the global pharmaceutical industry
|
January 2001 |
£45 |
9.8 % |
Obesity Drug Discoveries: what the future holds
|
August 2007 |
£1425 |
9.5 % |
Therapeutic Monoclonal Antibodies Report 2008-2023
|
July 2008 |
£2999 |
9.45 % |
Biomarkers
|
January 2008 |
£2225 |
9.1 % |
Triple Analysis: Apoptosis Agents, Protein Kinase Inhibitors and Anti-Angiogenic Agents in Oncology
|
December 2006 |
£4345 |
9.1 % |
When Patients Becomes Plaintiffs
A Primer on Drug and Medical Device Liability
|
October 2006 |
£1095 |
9 % |
hERG Screening
|
January 2008 |
£1980 |
8.75 % |
Brazil Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£2010 |
8.75 % |
South Africa Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£2010 |
8.75 % |
Netherlands Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£2010 |
8.75 % |
China Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£2010 |
8.75 % |
Indian Biopharmaceuticals Industry Report
|
January 2007 |
£400 |
8.4 % |
Australia Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£2010 |
8.4 % |
Immunotherapy of Cancer
|
March 2007 |
£3255 |
8.4 % |
Online Marketing and eDetailing Europe
|
July 2007 |
£75 |
8.4 % |
In Vitro Diagnostics Market Report & Analysis 2008-2023
|
June 2008 |
£1499 |
8.05 % |
In-Vitro Diagnostics Market Report & Analysis 2008-2023
|
June 2008 |
£1499 |
8.05 % |
Animal Biotechnology
Technologies, Markets and Companies
|
September 2008 |
£900 |
8.05 % |
World Generic Market Report 2007
|
November 2006 |
£595 |
8.05 % |
Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents
|
October 2006 |
£2895 |
8.05 % |
Strategic Outlook on Protein Kinase Inhibitors in Oncology
|
February 2006 |
£1635 |
7.7 % |
Innovations and Trends in Clinical Trials
Microdosing (Phase 0 Trials), Adaptive Trials, Phase IV Trials and the Role of Information Technology
|
March 2007 |
£1510 |
7.7 % |
Bioinformatics Markets
Strategies, Business Models and Trends for the Future
|
June 2006 |
£2280 |
7.35 % |
Clinical Trials in India
Industry Report
|
November 2005 |
£400 |
7.35 % |
South Africa Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1015 |
7.35 % |
Nanotechnology and MEMS 2003
The Race to Commercialize the Ultra-Small
|
August 2003 |
£1005 |
7.35 % |
Brazil Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1015 |
7.35 % |
Industry Insight Clinical Trials in India 2007
|
May 2007 |
£400 |
7.35 % |
Australia Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1015 |
7 % |
Clinical Trails in India
|
January 2008 |
£600 |
7 % |
Antiviral Therapeutics
Technologies, Markets and Companies
|
September 2008 |
£1880 |
7 % |
Netherlands Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2012
|
May 2008 |
£1015 |
7 % |
Analytical R&D Tool - Analysis of Prostate Cancer R&D
The Complete Guide
|
February 2004 |
£3355 |
7 % |
Pharmacoeconomics & Success in the Marketplace
|
January 2005 |
£1499 |
7 % |
Drug Discovery
Current trends and future prospects
|
February 2001 |
£300 |
7 % |
PAREXEL's Bio/Pharma R&D Statistical Sourcebook 2008/2009
|
June 2008 |
£285 |
6.65 % |
Pharmaceutical Pricing: global perspectives
|
September 2004 |
£625 |
6.65 % |
Chemotherapy Market Insights, 2006-2016
A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities
|
April 2006 |
£1900 |
6.65 % |
Targeted Therapies in Oncology
A World Review
|
December 2006 |
£4155 |
6.65 % |
Pharmaceutical R&D Productivity
The Path to Innovation
|
October 2005 |
£1945 |
6.5 % |
Cancer Vaccine Developments to 2011
|
September 2007 |
£1296 |
6.3 % |
Parexel's Pharmaceutical R&D Statistical Sourcebook 2007/2008
|
May 2007 |
£285 |
6.3 % |
World Biotech Market 2005, The
|
June 2005 |
£4999 |
5.95 % |
Pharmacogenomics: New Technologies
In the Development of Personalized Therapies
|
August 2005 |
£3045 |
5.95 % |
Antiageing and Life Enhancement Pharmacotherapeutics
|
January 2006 |
£4600 |
5.95 % |
Pharmaceutical Pricing Compendium
A practical guide to the pricing and reimbursement of medicines
|
March 2003 |
£125 |
5.95 % |
Triple Analysis: Protein Kinase Inhibitors, Antibodies and Vaccines in Oncology
|
August 2006 |
£2895 |
5.95 % |
Triple Progress Analysis: Lymphoma Therapeutics, Protein Kinase Inhibitors & Therapeutic Antibodies
|
May 2006 |
£2895 |
5.95 % |
Live-Licensing & In-life Testing
R&D Processes and Regulation for New Drugs, 2008-2020
|
January 2008 |
£1499 |
5.95 % |
Therapeutic Proteins
|
February 2005 |
£1999 |
5.6 % |
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies
More drugs on the market, more targets in the pipeline
|
October 2006 |
£8000 |
5.6 % |
Drug Delivery Technologies: Players, products & prospects to 2015
|
November 2007 |
£1795 |
5.6 % |
Pain Therapeutics
Drugs, Markets and Companies
|
September 2008 |
£1075 |
5.25 % |
Cancer Cell Therapy Markets
|
March 2008 |
£2280 |
4.9 % |
Pipeline Insight: Cancer Overview
Increasing Diversity Offers Both High Risk And Reward
|
September 2007 |
£7600 |
4.55 % |
Global Market for Advanced Wound Care Products 2008, The
A complete review of this fast growing, highly innovative sector
|
April 2008 |
£695 |
4.55 % |
Proteomics
Technologies, Markets and Companies
|
September 2008 |
£2345 |
3.85 % |
Executive Guide to Molecular Imaging; The
|
April 2005 |
£395 |
3.5 % |
|
|
|
|
